@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP353833.RAUKA1gR-FcV23hubuVBRaM-clXIAkFZGibiE4QkFLtw0130_head { this: np:hasAssertion dgn-np:NP353833.RAUKA1gR-FcV23hubuVBRaM-clXIAkFZGibiE4QkFLtw0130_assertion; np:hasProvenance dgn-np:NP353833.RAUKA1gR-FcV23hubuVBRaM-clXIAkFZGibiE4QkFLtw0130_provenance; np:hasPublicationInfo dgn-np:NP353833.RAUKA1gR-FcV23hubuVBRaM-clXIAkFZGibiE4QkFLtw0130_publicationInfo; a np:Nanopublication . dgn-np:NP353833.RAUKA1gR-FcV23hubuVBRaM-clXIAkFZGibiE4QkFLtw0130_assertion a np:Assertion . dgn-np:NP353833.RAUKA1gR-FcV23hubuVBRaM-clXIAkFZGibiE4QkFLtw0130_provenance a np:Provenance . dgn-np:NP353833.RAUKA1gR-FcV23hubuVBRaM-clXIAkFZGibiE4QkFLtw0130_publicationInfo a np:PublicationInfo . } dgn-np:NP353833.RAUKA1gR-FcV23hubuVBRaM-clXIAkFZGibiE4QkFLtw0130_assertion { miriam-gene:1234 a ncit:C16612 . lld:C0151317 a ncit:C7057 . dgn-gda:DGNaade0b3a259bb7f675355ac8a10b14e2 sio:SIO_000628 miriam-gene:1234, lld:C0151317; a sio:SIO_001121 . } dgn-np:NP353833.RAUKA1gR-FcV23hubuVBRaM-clXIAkFZGibiE4QkFLtw0130_provenance { dgn-np:NP353833.RAUKA1gR-FcV23hubuVBRaM-clXIAkFZGibiE4QkFLtw0130_assertion dcterms:description "[The Panel makes the following recommendations concerning the indications for resistance testing: for HIV-1 (i) test earliest sample for protease and reverse transcriptase drug resistance in drug-naive patients with acute or chronic infection; (ii) test protease and reverse transcriptase drug resistance at virologic failure, and other drug targets (integrase and envelope) if such drugs were part of the failing regimen; (iii) consider testing for CCR5 tropism at virologic failure or when a change of therapy has to be made in absence of detectable viral load, and in the latter case test DNA or last detectable plasma RNA; (iv) consider testing earliest detectable plasma RNA when a successful nonnucleoside reverse transcriptase inhibitor-containing therapy was inappropriately interrupted; (v) genotype source patient when postexposure prophylaxis is considered; for HIV-2, (vi) consider resistance testing where treatment change is needed after treatment failure.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:21587341; prov:wasDerivedFrom dgn-void:befree-20140225; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-20140225 pav:importedOn "2014-02-25"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP353833.RAUKA1gR-FcV23hubuVBRaM-clXIAkFZGibiE4QkFLtw0130_publicationInfo { this: dcterms:created "2014-10-02T12:35:27+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetrdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v2.1.0.0" . dgn-void:disgenetrdf pav:version "v2.1.0" . }